Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR+ NK cells
- Development stage
- Preclinical
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR+ NK cells (Chimeric Antigen Receptor Natural Killer cells) are an engineered cellular immunotherapy designed to enhance the innate anti-tumor activity of natural killer cells. By expressing a synthetic CAR construct, these cells are redirected to specifically recognize and lyse tumor cells expressing a target antigen, such as CD19 in B-cell malignancies. CAR-NK cells offer potential advantages over CAR-T therapies, including a reduced risk of cytokine release syndrome (CRS) and graft-versus-host disease (GvHD), enabling the development of "off-the-shelf" allogeneic products. In research settings, they are frequently used as a benchmark for evaluating novel engineered lymphocyte subsets, such as NKG2C+ CD8 T cells.
- Other names
- CAR-NK cellsChimeric Antigen Receptor Natural Killer cells
02
Targets
Beyond the preview
Go deeper on CAR+ NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR+ NK cells.